Clostridium difficile (C.diff) is well documented as an important nosocomial pathogen in Western countries responsible for substantial patient morbidity and mortality especially the elderly (> 65yrs) and immunocompromised. However, much less is known regarding disease burden in Emerging (BRIC-M) and "Rest of World" countries where manufacturers of vaccines and biologics are increasingly focused.
This enhanced MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Clostridium difficile vaccines across Emerging and "Rest of World" countries. The model contains value ($ m) and volume (mio doses) predictions for all indications i.e. prophylatic (PX) and therapeutic (TX) of a potential C.diff vaccine and provides incidence estimates of CDI (number of cases) to 2030. The analysis is also informed by in-depth primary research with experts (4 interviews) in C.diff within in the region who provide an up to date picture of current understanding with regard to C.diff epidemiology, trends and outlook for new vaccines. This product is an essential component for any manufacturer wishing to understand further the potential of new CDI vaccines and treatments outside the Western economies.